According to the positive results from these studies, treatment with anti-PD-1 antibodies—as mono- or combination-therapy with Ipilimumab—is nowadays a major therapeutic option for advanced melanoma patients with good performance status [15]. The gene discussed is PDCD1; the disease is melanoma.